UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

13 Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

Read More Share:

Oct

03 From Bandages to Bravery: HS Patients Command Times Square in Unforgettable Event

Read More Share:

Sep

17 BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints

Read More Share:

Sep

17 BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years

Read More Share:

Sep

10 Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care

Read More Share:

Sep

10 Gen Z and Millennial Patients Find “Rheum for Improvement” in Disease Management

Read More Share:

Sep

08 The profound impact on the lives of people living with thymidine kinase 2 deficiency (TK2d)

Read More Share:

Sep

03 The Sniff That Saves: Honoring Service Dogs This Awareness Month

Read More Share:

Aug

29 Decades of Dedication: UCB’s Ongoing Commitment to Epilepsy through the Family Epilepsy Scholarship Program™

Read More Share:

Aug

12 Our Growth Helps Elevate Patient Lives

Read More Share:

Categories

Archives

Oct

13

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

Oct

03

From Bandages to Bravery: HS Patients Command Times Square in Unforgettable Event

Sep

17

BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints

Sep

17

BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years

Sep

10

Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care

Sep

10

Gen Z and Millennial Patients Find “Rheum for Improvement” in Disease Management

Sep

08

The profound impact on the lives of people living with thymidine kinase 2 deficiency (TK2d)

Sep

03

The Sniff That Saves: Honoring Service Dogs This Awareness Month

Aug

29

Decades of Dedication: UCB’s Ongoing Commitment to Epilepsy through the Family Epilepsy Scholarship Program™

Aug

12

Our Growth Helps Elevate Patient Lives

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Oct

13

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

Oct

03

From Bandages to Bravery: HS Patients Command Times Square in Unforgettable Event

Sep

17

BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints

Sep

17

BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years

Sep

10

Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care

Sep

10

Gen Z and Millennial Patients Find “Rheum for Improvement” in Disease Management

Sep

08

The profound impact on the lives of people living with thymidine kinase 2 deficiency (TK2d)

Sep

03

The Sniff That Saves: Honoring Service Dogs This Awareness Month

Aug

29

Decades of Dedication: UCB’s Ongoing Commitment to Epilepsy through the Family Epilepsy Scholarship Program™

Aug

12

Our Growth Helps Elevate Patient Lives

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact